All In Biotech

Drug Trial Radar · NCT01444846

Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

83

Actual

Start

Sep 2011

Primary completion

Dec 2013

Study completion Mar 2014

Sponsor

Sponsor type
Industry
Collaborators
University of Florida
First posted
Oct 3, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 31 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Exposure to loud sounds can cause hearing loss. The purpose of this research study is to evaluate potential prevention of temporary changes in hearing that may occur after listening to music through an iPod or personal music player. We will measure temporary changes in hearing in subjects who listen to music and take either the study drug, SPI-1005, or a placebo for 4 days. SPI-1005 is a proprietary preparation of ebselen that allows it to be taken by mouth. Ebselen contains the mineral selenium and behaves like Glutathione Peroxidase, an enzyme that helps to rid the body of damaging chemicals caused by loud sounds.

Conditions

  • Temporary Auditory Threshold Shift

Interventions

  • SPI-1005 Low doseDrug

    Oral capsules, 200 mg ebselen, twice daily, 4 days

  • SPI-1005 Middle doseDrug

    Oral capsules, 400 mg ebselen, twice daily, 4 days

  • SPI-1005 High doseDrug

    Oral capsules, 600 mg ebselen, twice daily, 4 days

  • PlaceboDrug

    Oral capsules, 0 mg ebselen, twice daily, 4 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Temporary Threshold Shift at 4 kHz--Intent To Treat (ITT) PopulationTime frame: 15 minutes post Controlled Sound Challenge
  2. Change in Temporary Threshold Shift at 4 kHz--Per Protocol (PP) PopulationTime frame: 15 minutes post Controlled Sound Challenge

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.